Covaxin Human Trials
-
{
- All
- News
-
Covaxin Crosses Half-Way Mark In Phase-3 Trials, Says Bharat Biotech
India's first and only phase III trial of a COVID-19 vaccine has crossed 13,000 subjects - the half-way mark - and proceeding successfully across multiple sites in India, Bharat Biotech, the maker of the inoculant Covaxin, announced today. The trials in the first and second phases had led to promising results.
-
Man Receives First Dose Of Covaxin In Phase-I Of Human Trial At Delhi AIIMS
The phase-I human clinical trial of India's first indigenously-developed vaccine against novel coronavirus, Covaxin, began at Delhi AIIMS on Friday and the first dose of the injection was administered to a man who is in his 30s.
-
Covaxin Crosses Half-Way Mark In Phase-3 Trials, Says Bharat Biotech
India's first and only phase III trial of a COVID-19 vaccine has crossed 13,000 subjects - the half-way mark - and proceeding successfully across multiple sites in India, Bharat Biotech, the maker of the inoculant Covaxin, announced today. The trials in the first and second phases had led to promising results.
-
Man Receives First Dose Of Covaxin In Phase-I Of Human Trial At Delhi AIIMS
The phase-I human clinical trial of India's first indigenously-developed vaccine against novel coronavirus, Covaxin, began at Delhi AIIMS on Friday and the first dose of the injection was administered to a man who is in his 30s.
